The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress

Pina Ziranu, Mario Scartozzi, Marco Puzzoni et al.|Annals of Oncology|2018

Cited by 4